FI62314C - Foerfarande foer framstaellning av terapeutiskt anvaendbara ny 3-((3-alkylisokinol-5-yl)imino)-1,5,10,10a-tetrahydrotia zoo(3,4-b)isokinoliner - Google Patents
Foerfarande foer framstaellning av terapeutiskt anvaendbara ny 3-((3-alkylisokinol-5-yl)imino)-1,5,10,10a-tetrahydrotia zoo(3,4-b)isokinoliner Download PDFInfo
- Publication number
- FI62314C FI62314C FI780182A FI780182A FI62314C FI 62314 C FI62314 C FI 62314C FI 780182 A FI780182 A FI 780182A FI 780182 A FI780182 A FI 780182A FI 62314 C FI62314 C FI 62314C
- Authority
- FI
- Finland
- Prior art keywords
- imino
- formula
- isoquinoline
- tetrahydrothiazolo
- prepared
- Prior art date
Links
- -1 IMINO Chemical class 0.000 title claims description 28
- 238000000034 method Methods 0.000 title claims description 13
- 238000002360 preparation method Methods 0.000 title claims description 7
- 101000740162 Homo sapiens Sodium- and chloride-dependent transporter XTRP3 Proteins 0.000 title 1
- 102100037189 Sodium- and chloride-dependent transporter XTRP3 Human genes 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 34
- 150000003839 salts Chemical class 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 claims description 6
- 229910052801 chlorine Inorganic materials 0.000 claims description 6
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- DTVYNUOOZIKEEX-UHFFFAOYSA-N 5-aminoisoquinoline Chemical compound N1=CC=C2C(N)=CC=CC2=C1 DTVYNUOOZIKEEX-UHFFFAOYSA-N 0.000 claims description 3
- 230000002378 acidificating effect Effects 0.000 claims description 3
- 150000002537 isoquinolines Chemical class 0.000 claims description 3
- 150000001450 anions Chemical class 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical group O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 14
- 241000700159 Rattus Species 0.000 description 13
- 239000013078 crystal Substances 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 10
- 239000003960 organic solvent Substances 0.000 description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 8
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 8
- QPGUKSFXJCUUMG-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinolin-3-ylmethyl hydrogen sulfate Chemical compound C1=CC=C2CNC(COS(=O)(=O)O)CC2=C1 QPGUKSFXJCUUMG-UHFFFAOYSA-N 0.000 description 7
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 7
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 7
- DOJPVHCIGMTXAG-UHFFFAOYSA-N 3-methylsulfanyl-1,5,10,10a-tetrahydro-[1,3]thiazolo[3,4-b]isoquinolin-4-ium Chemical compound C1C2=CC=CC=C2CC2[N+]1=C(SC)SC2 DOJPVHCIGMTXAG-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 6
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- AWJUIBRHMBBTKR-UHFFFAOYSA-N iso-quinoline Natural products C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 6
- 238000002844 melting Methods 0.000 description 6
- 230000008018 melting Effects 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- ZSKDXMLMMQFHGW-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinolin-3-ylmethanol Chemical compound C1=CC=C2CNC(CO)CC2=C1 ZSKDXMLMMQFHGW-UHFFFAOYSA-N 0.000 description 4
- RLQZIECDMISZHS-UHFFFAOYSA-N 2-phenylcyclohexa-2,5-diene-1,4-dione Chemical compound O=C1C=CC(=O)C(C=2C=CC=CC=2)=C1 RLQZIECDMISZHS-UHFFFAOYSA-N 0.000 description 4
- MKZBYSNGUDMVDZ-UHFFFAOYSA-N 3-ethylisoquinolin-5-amine Chemical compound C1=CC=C2C=NC(CC)=CC2=C1N MKZBYSNGUDMVDZ-UHFFFAOYSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 230000003187 abdominal effect Effects 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000000679 carrageenan Substances 0.000 description 4
- 229940113118 carrageenan Drugs 0.000 description 4
- 235000010418 carrageenan Nutrition 0.000 description 4
- 229920001525 carrageenan Polymers 0.000 description 4
- 230000008602 contraction Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 125000001841 imino group Chemical group [H]N=* 0.000 description 4
- AWJUIBRHMBBTKR-UHFFFAOYSA-O isoquinolin-2-ium Chemical compound C1=[NH+]C=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-O 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 4
- RKZRSFDITVGOHP-UHFFFAOYSA-N 1,5,10,10a-tetrahydro-[1,3]thiazolo[3,4-b]isoquinoline-3-thione Chemical compound C1=CC=C2CN3C(=S)SCC3CC2=C1 RKZRSFDITVGOHP-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 206010000269 abscess Diseases 0.000 description 3
- 125000004414 alkyl thio group Chemical group 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000155 melt Substances 0.000 description 3
- 229960005190 phenylalanine Drugs 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- WRIZFUVYABPOLN-UHFFFAOYSA-N 2h-isoquinoline-3-thione Chemical compound C1=CC=C2C=NC(S)=CC2=C1 WRIZFUVYABPOLN-UHFFFAOYSA-N 0.000 description 2
- RIXACYCTQSOLND-UHFFFAOYSA-N 3-butylisoquinolin-5-amine Chemical compound C1=CC=C2C=NC(CCCC)=CC2=C1N RIXACYCTQSOLND-UHFFFAOYSA-N 0.000 description 2
- ZQLKOMXEZYQQBJ-UHFFFAOYSA-N 3-methylisoquinolin-5-amine Chemical compound C1=CC=C2C=NC(C)=CC2=C1N ZQLKOMXEZYQQBJ-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- UYDOPYNXEDBOPX-UHFFFAOYSA-N N-(3-ethylisoquinolin-5-yl)-3-(hydroxymethyl)-3,4-dihydro-1H-isoquinoline-2-carbothioamide Chemical compound C(C)C=1N=CC2=CC=CC(=C2C=1)NC(=S)N1CC2=CC=CC=C2CC1CO UYDOPYNXEDBOPX-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 150000002540 isothiocyanates Chemical class 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- IHCCLXNEEPMSIO-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 IHCCLXNEEPMSIO-UHFFFAOYSA-N 0.000 description 1
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical compound [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- NXPGJFIKBCDNOJ-UHFFFAOYSA-N 3-octylisoquinolin-5-amine Chemical compound C1=CC=C2C=NC(CCCCCCCC)=CC2=C1N NXPGJFIKBCDNOJ-UHFFFAOYSA-N 0.000 description 1
- SSIPWNMRZDPBHH-UHFFFAOYSA-N 3-propylisoquinolin-5-amine Chemical compound C1=CC=C2C=NC(CCC)=CC2=C1N SSIPWNMRZDPBHH-UHFFFAOYSA-N 0.000 description 1
- ASNHGEVAWNWCRQ-UHFFFAOYSA-N 4-(hydroxymethyl)oxolane-2,3,4-triol Chemical compound OCC1(O)COC(O)C1O ASNHGEVAWNWCRQ-UHFFFAOYSA-N 0.000 description 1
- DFGKGUXTPFWHIX-UHFFFAOYSA-N 6-[2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]acetyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)C1=CC2=C(NC(O2)=O)C=C1 DFGKGUXTPFWHIX-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 description 1
- 229930182832 D-phenylalanine Natural products 0.000 description 1
- DDLUPGYXJUGRNH-UHFFFAOYSA-N N-(3-octylisoquinolin-5-yl)-1,5,10,10a-tetrahydro-[1,3]thiazolo[3,4-b]isoquinolin-3-imine Chemical compound C(CCCCCCC)C=1N=CC2=CC=CC(=C2C=1)N=C1SCC2N1CC=1C=CC=CC=1C2 DDLUPGYXJUGRNH-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- FIWILGQIZHDAQG-UHFFFAOYSA-N NC1=C(C(=O)NCC2=CC=C(C=C2)OCC(F)(F)F)C=C(C(=N1)N)N1N=C(N=C1)C1(CC1)C(F)(F)F Chemical compound NC1=C(C(=O)NCC2=CC=C(C=C2)OCC(F)(F)F)C=C(C(=N1)N)N1N=C(N=C1)C1(CC1)C(F)(F)F FIWILGQIZHDAQG-UHFFFAOYSA-N 0.000 description 1
- MVNVXVPOPFEKQD-UHFFFAOYSA-N NC1=C2C=CN=CC2=CC=C1.C(=S)=S Chemical compound NC1=C2C=CN=CC2=CC=C1.C(=S)=S MVNVXVPOPFEKQD-UHFFFAOYSA-N 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 101100173585 Schizosaccharomyces pombe (strain 972 / ATCC 24843) fft1 gene Proteins 0.000 description 1
- TZEYHTCZIQZAPS-UHFFFAOYSA-N [1,3]thiazolo[4,5-h]isoquinoline Chemical class C1=CN=CC2=C(SC=N3)C3=CC=C21 TZEYHTCZIQZAPS-UHFFFAOYSA-N 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- VNWKTOKETHGBQD-AKLPVKDBSA-N carbane Chemical compound [15CH4] VNWKTOKETHGBQD-AKLPVKDBSA-N 0.000 description 1
- QGJOPFRUJISHPQ-NJFSPNSNSA-N carbon disulfide-14c Chemical compound S=[14C]=S QGJOPFRUJISHPQ-NJFSPNSNSA-N 0.000 description 1
- 239000012320 chlorinating reagent Substances 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- GVLGAFRNYJVHBC-UHFFFAOYSA-N hydrate;hydrobromide Chemical compound O.Br GVLGAFRNYJVHBC-UHFFFAOYSA-N 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- MBXNQZHITVCSLJ-UHFFFAOYSA-N methyl fluorosulfonate Chemical compound COS(F)(=O)=O MBXNQZHITVCSLJ-UHFFFAOYSA-N 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012261 resinous substance Substances 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
- C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Pain & Pain Management (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7701516A FR2378030A1 (fr) | 1977-01-20 | 1977-01-20 | Nouveau derive de l'isoquinoleine, sa preparation et les compositions qui le contiennent |
| FR7701516 | 1977-01-20 | ||
| FR7739028 | 1977-12-23 | ||
| FR7739028A FR2412545A1 (fr) | 1977-12-23 | 1977-12-23 | Nouveaux derives de l'isoquinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI780182A7 FI780182A7 (fi) | 1978-07-21 |
| FI62314B FI62314B (fi) | 1982-08-31 |
| FI62314C true FI62314C (fi) | 1982-12-10 |
Family
ID=26219809
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI780182A FI62314C (fi) | 1977-01-20 | 1978-01-20 | Foerfarande foer framstaellning av terapeutiskt anvaendbara ny 3-((3-alkylisokinol-5-yl)imino)-1,5,10,10a-tetrahydrotia zoo(3,4-b)isokinoliner |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US4153698A (cs) |
| JP (1) | JPS5914037B2 (cs) |
| AR (2) | AR217460A1 (cs) |
| AT (1) | AT361481B (cs) |
| AU (1) | AU510044B2 (cs) |
| CA (1) | CA1091674A (cs) |
| CH (1) | CH633010A5 (cs) |
| CS (2) | CS195350B2 (cs) |
| DE (1) | DE2802453C3 (cs) |
| DK (1) | DK143343C (cs) |
| ES (2) | ES466192A1 (cs) |
| FI (1) | FI62314C (cs) |
| GB (1) | GB1574281A (cs) |
| GR (1) | GR61726B (cs) |
| HU (1) | HU174219B (cs) |
| IE (1) | IE46375B1 (cs) |
| IL (1) | IL53841A (cs) |
| LU (1) | LU78895A1 (cs) |
| NL (1) | NL7800383A (cs) |
| NO (1) | NO780202L (cs) |
| NZ (1) | NZ186282A (cs) |
| OA (1) | OA05859A (cs) |
| PT (1) | PT67545B (cs) |
| SE (1) | SE7800681L (cs) |
| SU (2) | SU730309A3 (cs) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU797580A3 (ru) * | 1977-11-10 | 1981-01-15 | Рон-Пуленк Эндюстри (Фирма) | Способ получени производных изохино-лиНА, иХ СОлЕй, РАцЕМАТОВ или ОпТичЕС-КиХ изОМЕРОВ |
| FR2456098A2 (fr) * | 1977-12-23 | 1980-12-05 | Rhone Poulenc Ind | Nouveaux derives de l'isoquinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent |
| NL7908655A (nl) * | 1978-12-07 | 1980-06-10 | Rhone Poulenc Ind | Nieuwe thienopyridine-derivaten, de bereiding ervan, alsmede farmaceutische preparaten, die de nieuwe derivaten bevatten. |
| FR2456111A1 (fr) * | 1979-05-09 | 1980-12-05 | Rhone Poulenc Ind | Nouveaux derives de l'indole, leur preparation et les medicaments qui les contiennent |
| NL8002540A (nl) * | 1979-05-09 | 1980-11-11 | Rhone Poulenc Ind | Nieuwe isochinoline derivaten, werkwijzen ter bereiding ervan en farmaceutische preparaten, die de nieuwe derivaten bevatten. |
| AU6496380A (en) * | 1979-12-04 | 1981-06-11 | Rhone-Poulenc Industries | Thiazolo(3,4-b) isoquinoline derivatives |
| US4269842A (en) * | 1979-12-05 | 1981-05-26 | Rhone-Poulenc Industries | Method for treating rhinoviral complaints |
| US6582728B1 (en) * | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL169076C (nl) * | 1975-08-06 | 1982-06-01 | Rhone Poulenc Ind | Werkwijze voor het bereiden of vervaardigen van farmacologische preparaten met een analgetische en antipyretische werking, alsmede werkwijze voor het bereiden van geneeskrachtige verbindingen, welke geschikt zijn voor gebruik in dergelijke preparaten. |
-
1978
- 1978-01-12 NL NL7800383A patent/NL7800383A/xx not_active Application Discontinuation
- 1978-01-17 CS CS785983A patent/CS195350B2/cs unknown
- 1978-01-17 CS CS78323A patent/CS195349B2/cs unknown
- 1978-01-17 OA OA56380A patent/OA05859A/xx unknown
- 1978-01-18 GR GR55196A patent/GR61726B/el unknown
- 1978-01-18 IL IL53841A patent/IL53841A/xx unknown
- 1978-01-19 SE SE7800681A patent/SE7800681L/xx unknown
- 1978-01-19 CA CA295,296A patent/CA1091674A/fr not_active Expired
- 1978-01-19 LU LU78895A patent/LU78895A1/xx unknown
- 1978-01-19 PT PT67545A patent/PT67545B/pt unknown
- 1978-01-19 AT AT39378A patent/AT361481B/de not_active IP Right Cessation
- 1978-01-19 SU SU782567352A patent/SU730309A3/ru active
- 1978-01-19 GB GB2241/78A patent/GB1574281A/en not_active Expired
- 1978-01-19 NO NO780202A patent/NO780202L/no unknown
- 1978-01-19 DK DK27178A patent/DK143343C/da not_active IP Right Cessation
- 1978-01-19 CH CH56178A patent/CH633010A5/fr not_active IP Right Cessation
- 1978-01-19 HU HU78RO958A patent/HU174219B/hu unknown
- 1978-01-20 AU AU32611/78A patent/AU510044B2/en not_active Expired
- 1978-01-20 IE IE126/78A patent/IE46375B1/en unknown
- 1978-01-20 JP JP53005113A patent/JPS5914037B2/ja not_active Expired
- 1978-01-20 FI FI780182A patent/FI62314C/fi not_active IP Right Cessation
- 1978-01-20 ES ES466192A patent/ES466192A1/es not_active Expired
- 1978-01-20 AR AR270785A patent/AR217460A1/es active
- 1978-01-20 US US05/871,136 patent/US4153698A/en not_active Expired - Lifetime
- 1978-01-20 NZ NZ186282A patent/NZ186282A/xx unknown
- 1978-01-20 DE DE2802453A patent/DE2802453C3/de not_active Expired
- 1978-04-07 ES ES468630A patent/ES468630A1/es not_active Expired
-
1979
- 1979-02-05 AR AR275407A patent/AR219963A1/es active
- 1979-02-08 SU SU792720496A patent/SU776560A3/ru active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI61896B (fi) | Foerfarande foer framstaellning av antiinflammatoriska foer reumavaord laempliga och antitrombotiska 4-hydroxi-2h-1,2-benzodiazin-3-karboxamid-1,1-dioxider | |
| ES2276530T3 (es) | Azabiciclos qu4e modelan la inhibicion de la adherencia celular. | |
| Gray et al. | Phencyclidine-like effects of tetrahydroisoquinolines and related compounds | |
| FI100969B (fi) | Menetelmä valmistaa terapeuttisesti aktiivista pyratsolo£1,5-a|pyridii niyhdistettä | |
| PT87988B (pt) | Processo para a preparacao de diazois e de composicoes farmaceuticas que os contem | |
| FI62314C (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbara ny 3-((3-alkylisokinol-5-yl)imino)-1,5,10,10a-tetrahydrotia zoo(3,4-b)isokinoliner | |
| FI63416C (fi) | Som soetningsmedel anvaendbara 4,5-dimetyl- och 5-metyl-tieno(3,2-d)isotiatsol-3(2h)-on-1,1-dioxider och deras framstaellningsfoerfarande | |
| KR100204633B1 (ko) | 신규 벤즈이미다졸 유도체 그의 제조방법 그의 신규 중간체 그의 약물 용도 및 그를 함유하는 제약 조성물 | |
| FI63029B (fi) | Foerfarande foer framstaellning av ulcushaemmande n-substituerade 5,11-dihydro-(piperazin-1'-yl-alkanoyl)-6h-pyrido(2,3-b)(1,4)-benzodiazepin-6-on-derivater | |
| DE68918257T2 (de) | 4,5,6,7-Tetrahydrobenzimidazol-Derivate und ihre Herstellung. | |
| Kashaw et al. | Design, synthesis and potential CNS activity of some novel 1-(4-substituted-phenyl)-3-(4-oxo-2-propyl-4H-quinazolin-3-yl)-urea | |
| FI63588B (fi) | Foerfarande foer framstaellning av nya terapeutiskt anvaendbara heterosyklylimino-1,6,11,11a-tetrahydro(1,3-tiazino)(3,4-b)isokinoliner | |
| KR20050057654A (ko) | 고컨덕턴스의 칼슘-활성화된 ｋ 채널 개방제 | |
| JPH0227969B2 (cs) | ||
| WO1994017075A1 (en) | Diazepin derivatives and antiviral compositions | |
| FI69077B (fi) | Foerfarande foer framstaellning av tieno-(2,3-c) och (3,2-c) pyridinderivat | |
| PL144860B1 (en) | Method of obtaining novel derivatives of iminothiasolidyne | |
| FI63566B (fi) | Foerfarande foer framstaellning av nya terapeutiskt anvaendbara dibenso(d,g)(1,3,6)dioxazocin-derivat och av deras fysiologiskt godtagbara syraadditionssalter | |
| PL116688B1 (en) | Process for the preparation of trinuclear compounds with nitrogen atom in nodal position | |
| US4350698A (en) | Antiallergic imidosulfamides | |
| US5064836A (en) | Imidazopyridine for use as an anaesthetic | |
| DK150158B (da) | Analogifremgangsmaade til fremstilling af 4-phenylthieno-(2,3-c)piperidiner eller fysiologisk acceptable syreadditionssalte deraf | |
| NZ206305A (en) | Benzazepine and benzodiazepine derivatives and pharmaceutical compositions | |
| FI63569C (fi) | Foerfarande foer framstaellning av farmaceutiskt anvaendbara 6,11-dihydro-11-oxodibenz(b e)oxepinalkylkarboxylsyror och deas estrar | |
| NL8205038A (nl) | Esters van 4-hydroxymethyl-1-ftalazonderivaten en zouten daarvan. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM | Patent lapsed |
Owner name: RHONE- POULENC INDUSTRIES |